|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ИНХС РАН |
||
212Pb: Production Approaches and Targeted Therapy Applicationsстатья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 1 июня 2022 г.
- Авторы: Kokov Konstantin V., Egorova Bayirta V., German Marina N., Klabukov Ilya D., Krasheninnikov Michael E., Larkin-Kondrov Antonius A., Makoveeva Kseniya A., Ovchinnikov Michael V., Sidorova Maria V., Chuvilin Dmitry Y.
- Журнал: Pharmaceutics
- Том: 14
- Номер: 1
- Год издания: 2022
- Издательство: MDPI
- Местоположение издательства: Basel, Switzerland
- Первая страница: 189
- DOI: 10.3390/pharmaceutics14010189
- Аннотация: Over the last decade, targeted alpha therapy has demonstrated its high effectiveness intreating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughteralpha-emitter short-lived 212Bi (T1/2 = 1 h), provides the possibility for the synthesis and purificationof complex radiopharmaceuticals with minimum loss of radioactivity during preparation. As a benefitfor clinical implementation, it can be milked from a radionuclide generator in different ways.The main approaches applied for these purposes are considered and described in this review, includingchromatographic, solution, and other techniques to isolate 212Pb from its parent radionuclide.Furthermore, molecules used for lead’s binding and radiochemical features of preparationand stability of compounds labeled with 212Pb are discussed. The results of preclinical studies withan estimation of therapeutic and tolerant doses as well as recently initiated clinical trials of targetedradiopharmaceuticals are presented.
- Добавил в систему: Егорова Байирта Владимировна